1. Preventing neurocognitive late effects in childhood cancer survivors.
- Author
-
Askins MA and Moore BD 3rd
- Subjects
- Age Factors, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Brain physiopathology, Brain Neoplasms mortality, Child, Cognition Disorders chemically induced, Cognition Disorders physiopathology, Drug Therapy methods, Drug Therapy trends, Humans, Iatrogenic Disease prevention & control, Nerve Fibers, Myelinated drug effects, Nerve Fibers, Myelinated pathology, Nerve Fibers, Myelinated radiation effects, Radiotherapy methods, Radiotherapy trends, Time, Brain drug effects, Brain radiation effects, Brain Neoplasms drug therapy, Brain Neoplasms radiotherapy, Cognition Disorders prevention & control, Drug-Related Side Effects and Adverse Reactions, Radiotherapy adverse effects
- Abstract
Neurocognitive late effects are common sequelae of cancer in children, especially in those who have undergone treatment for brain tumors or in those receiving prophylactic cranial radiation therapy to treat leukemia. Neurocognitive morbidity in attention, executive functioning, processing speed, working memory, and memory frequently occurs and contributes to declines in intellectual and academic abilities. Oncologists are faced with the challenge of using the most effective, often the most intense, therapy to achieve the primary goal of medical success, balanced with the desire to prevent adverse late effects. Not all children with similar diagnoses and treatment have identical neurocognitive outcomes; some do very poorly and some do well. Attention now turns to the reliable prediction of risk for poor outcomes and then, using risk-adapted therapy, to preserve neurocognitive function. Prevention of late effects through rehabilitative strategies, continuation of school, and pharmacotherapy will be explored.
- Published
- 2008
- Full Text
- View/download PDF